{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-23-015629","form_type":"8-K","ticker":"EDSA","cik":"0001540159","company_name":"Edesa Biotech, Inc.","filed_at":"2023-12-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.465425+00:00","generated_at":"2026-06-07T11:52:06.377330+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Edesa Biotech FY2023 net loss $8.4M ($2.93/sh); secures C$23M govt funding for Phase 3 ARDS trial","bullets":["Net loss narrowed to $8.4M ($2.93 per share) from $17.6M ($8.37) in FY2022; R&D expenses fell to $4.8M from $13.3M.","Canadian government committed up to C$23M (partially repayable) for Phase 3 study of ARDS drug EB05 (paridiprubart); FDA Fast Track granted.","Established $10M revolving credit facility; cash and equivalents $5.4M at Sept 30, 2023, with $0.3M raised post-year-end via equity distribution.","Plans to initiate Phase 2 trial for vitiligo drug EB06 (anti-CXCL10) and file IND for fibrotic diseases; evaluating partnership for dermatitis drug EB01 after positive Phase 2b.","Management to present at Dermatology Summit and JP Morgan week in January 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-23-015629","json":"https://secwatch.observer/filing/0001654954-23-015629.json","markdown":"https://secwatch.observer/filing/0001654954-23-015629.md","text":"https://secwatch.observer/filing/0001654954-23-015629.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1540159/000165495423015629/0001654954-23-015629-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1540159/000165495423015629/edsa_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T11:52:06.377330+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"40b3bb1469ab4931521c1926864a2957c39e3fd0","claim":"Edesa Biotech, Inc. reported fiscal year ended September 30, 2023 results: net income net loss of $8.4 million, EPS $2.93 per common share.","evidence_excerpt":"For the year ended September 30, 2023, Edesa reported a net loss of $8.4 million, or $2.93 per common share, compared to a net loss of $17.6 million, or $8.37 per common share, for the year ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1540159/000165495423015629/0001654954-23-015629-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal year ended September 30, 2023"},{"label":"Net income","value":"net loss of $8.4 million"},{"label":"EPS","value":"$2.93 per common share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}